 | Up a level |
Journal Article
Breyer, J., Monga, M., Mayr, R., Otto, W., Burger, M., Eckstein, M., Stoehr, R., Erben, P., Bolenz, C., Eidt, S., Sundaram, R., Baig, M., Galluzzi, A., Wirtz, R., Hartmann, A. and Santiago-Walker, A. (2020). Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC). Ann. Oncol., 31. S. S587 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Groneck, V. and Eidt, S. (2021). A 54-year-old man with odynophagia. Gastroenterologe, 16 (5). S. 387 - 390. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1861-969X
Marme, F., Schneeweiss, A., Aigner, J., Eidt, S., Altevogt, P., Sinn, P. and Wirtz, R. M. (2012). Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Schloesser, H. A., Shimabukuro-Vornhagen, A., Scherwitz, P., Koslowsky, T., Eidt, S., Stippel, D. L. and von Bergwelt-Baildon, M. S. (2014). Characterization of tumor associated b cells in colorectal cancer. Oncol. Res. Treat., 37. S. 45 - 46. BASEL: KARGER. ISSN 2296-5262
Wirtz, R. M., Aigner, J., Marme, F., Eidt, S., Altevogt, P., Sinn, P. and Schneeweiss, A. (2013). High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2012). CXCL13 mRNA predicts Docetaxel benefit in Triple Negative tumors. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2013). Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Wirtz, R. M., Scheffen, I., Marme, F., Laible, M., Sclombs, K., Schumacher, C., Schneeweiss, A., Eidt, S. and Sinn, H-P (2017). Predictive value of ultra-high ESR1 mRNA expression in early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445